Related Experiment Videos
[Thrombolytic therapy in acute myocardial infarct]
1III. interní katedra fakulty vseobecného lékarství Univerzity Karlovy, Praha.
Casopis Lekaru Ceskych
|April 20, 1990
Summary
Thrombolytic therapy significantly reduces short-term mortality in acute myocardial infarction by approximately 50%. Key factors influencing outcomes include treatment timing, myocardial function restoration, and residual stenosis, with aspirin showing benefit during follow-up.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Review of thrombolytic therapy for acute myocardial infarction.
- Evaluation of first, second, and third-generation thrombolytic agents.
Purpose:
- To evaluate available data on thrombolytic therapy.
- To discuss pharmacological and clinical characteristics of thrombolytic agents.
- To review cooperative study results on thrombolysis.
Summary:
- Thrombolytic treatment decreased short-term mortality by ~50% in acute myocardial infarction patients.
- Influencing factors: symptom onset to treatment interval, myocardial function restoration, residual stenosis, and concomitant medication.
- Aspirin demonstrated benefit during follow-up; immediate coronary angioplasty remains unresolved.
Impact:
- Thrombolytic therapy offers significant survival benefits in acute myocardial infarction.
- Understanding influencing factors can optimize patient outcomes.
- Intracerebral bleeding is a notable risk (up to 2%) with agents like streptokinase and tissue plasminogen activator.